Meeting
2015 ASCO Annual Meeting
MyD88/CD40-based costimulation to enhance survival and proliferation of chimeric antigen receptor (CAR)-modified T cells.
Authors
Aaron E Foster
Bellicum Pharmaceuticals, Houston, TX
Aaron E Foster , Peter Chang , Pei-Yi Lin , Jeannette Crisostomo , Aruna Mahendravada , An Lu , Mariam Khalil , Kevin Mark Slawin , David Spencer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Immunotherapy and Biologic Therapy
Citation
J Clin Oncol 33, 2015 (suppl; abstr 3064)
DOI
10.1200/jco.2015.33.15_suppl.3064
Abstract #
3064
Poster Bd #
390
Abstract Disclosures
Similar Posters
Poster
2016 Genitourinary Cancers Symposium
Inducible MyD88/CD40 to allow rimiducid-dependent activation for control of proliferation and survival of chimeric antigen receptor (CAR) T cells targeting prostate stem cell antigen (PSCA).
First Author: Kevin Mark Slawin
Poster
2020 ASCO Virtual Scientific Program
Eradication of medulloblastoma by NKG2D-specific CAR T-cells.
First Author: Hong-jiu Dai
Poster
2011 ASCO Annual Meeting
Effect of a costimulatory endodomain on the performance of T cells expressing CD19-directed chimeric antigen receptors (CARs) in subjects with relapsed/refractory B-cell malignancies
First Author: C. A. Ramos
Poster
2023 ASCO Annual Meeting
A phase Ib study of endogenous T cell therapy using SLC45A2-specific CD8 T cells for patients with metastatic uveal melanoma.
First Author: Suzanne Phillips